Three reasons to be happy today. 1/ I'm on holiday (long overdue)... 🏝️
Florian Naudet
@floriannaudet.bsky.social
Meta-researcher, Clinician, Professor at Rennes University, Senior member at Institut Universitaire de France, affiliate at METRICStanford. ORCID: 0000-0003-3760-3801 Posts are my own. Website: https://restores.univ-rennes.fr/
Long day at work. Not the easiest one. Not the worst ever... Now it's evening, I'm back on the SHARE-CTD Datathon 2 writting, with some good music that reminds me of California. Not a bad way to end the day. The endless teaser continues... 😉 www.deezer.com/fr/album/130...
Dark Necessities
Red Hot Chili Peppers - album - 2016 - 1 titre
deezer.com
Florian Naudet@floriannaudet.bsky.social · 2w agoNew preprint led by Tala Jajieh from the ResToRes project. By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years. www.medrxiv.org/content/10.6...
New preprint led by Tala Jajieh from the ResToRes project. By analysing RCTs with confirmed data fabrication, our new preprint reveals that most zombie trials arise from monocentric, recurrent patterns of misconduct and often remain undetected for many years. www.medrxiv.org/content/10.6...
4. The editorial is IMO another example of wishful thinking in biological psychiatry, providing an outlook of finding moderators to allow precision psychiatry. There are many reasons for being humble here: bsky.app/profile/ploe...
Martin Plöderl@ploederl.bsky.social · 6y ago1/ About personalized medicine/psychiatry: a new paper by @JonasRueppel, with a meta-view on the issue and insights obtained by interviewing psychiatrists https://journals.sagepub.com/doi/10.1177/0162243919845049 Longer thread with some background info
3. The editorial is about a individual patient meta-analysis of placebo-controlled trials (see thread below). This is the appropriate way to look at treatment effect heterogeneity. bsky.app/profile/ploe...
Martin Plöderl@ploederl.bsky.social · 2mo ago1. New IPD meta-analysis on antidepressants (ADs) to treat depression in children & adolescents. This is massive work and potentially important given the poor efficacy of ADs: < 2 points on the Childhood depression rating scale (CDRS) which ranges from 17 to 113 with a suggested MCID of 5 points ->
2. For example, there is a reference to a study on the association (!) bw age and improvement of symptoms with antidepressants. A lot of causal interpretation. However, what is needed is to look at interactions between age and response to drug/placebo. www.sciencedirect.com/science/arti...
The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder
Understanding how age affects antidepressant response in patients with major depressive disorder has been complicated by small and heterogeneous studi…
sciencedirect.com
The GRIOS call for evidence synthesis on #OpenScience has now closed & the response exceeded our expectations. Thanks to all who submitted a proposal! Over 70 received, ~1/3 on incentives & research assessment, 2/3 on data sharing. Evaluation results expected: Nov 2026 www.grios.org/grios-first-...
GRIOS first open call for evidence synthesis on Open Science has closed
The GRIOS open call for evidence synthesis on Open Science closed on 20 July 2026. We are grateful to all who submitted a proposal — the response has exceeded our expectations. Over 70 proposals we...
grios.org
Our living review has now synthesised 846 articles examining problems with systematic reviews. Reporting improved in some areas, but persistent concerns remain around methodological quality, transparency, spin, conflicts of interest, and global representation. authors.elsevier.com/a/1nTHE3BcJQ...
Please wait whilst we redirect you
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
authors.elsevier.com
11. Thanks to @floriannaudet.bsky.social and @richlyus.bsky.social for the excellent collaboration.
10. Here's a graphical depiction of the outlying findings, when compared to other pediatric fluoxetine trials.
1. We wrote a letter to the editor about this fluoxetine trial for children aged 4-6. Given the urgency and the expected delay in response, we also published it as a preprint, available here: doi.org/10.31234/osf... Which problems did we detect with this study ? 🧵
Chris Aiken, MD@chrisaikenmd.bsky.social · 3w agoHere's the first trial to test fluoxetine for #depression in children under 6: psych-partners.com/fluoxetine-f... Positive signal, but agitation is a risk, and a single study doesn't change the fact that Parent-Child Interaction #Therapy has the best evidence in this age group. #psychiatry #pmhnp
#TriNetX, which provides access to anonymized EHRs for >300M patients in the US & abroad, may be allowing inexperienced researchers potentially aided by #AI to churn out unreliable bias-ridden studies w unrivaled speed www.science.org/content/arti... @joelving.bsky.social @retractionwatch.com
Medical students are using a popular research tool to pump out misleading studies
Critics say TriNetX’s easy analyses of electronic medical records fuel quick-and-dirty publications from inexperienced authors
science.org
Huge congratulations to our fellow researcher @minoo-matbouriahi.bsky.social on her latest publication in JAMA Network Open! She teamed up with @floriannaudet.bsky.social John Ioannidis @ioanaacristea.bsky.social, and a stellar team to tackle a fascinating topic in #ResearchIntegrity #PeerOnSky
Nice editorial in @bmj.com: "Influence on regulatory decisions for drugs with limited evidence" by Sahar Barjesteh van Waalwijk van Doorn-Khosrovani and Timothée Olivier "Conflicts of interest and political and emotional pressures are key challenges www.bmj.com/content/393/...
Influence on regulatory decisions for drugs with limited evidence
Conflicts of interest and political and emotional pressures are key challenges Regulatory agencies face growing pressure to approve drugs despite major safety and efficacy concerns. Over decades, th...
bmj.com
“The combination of some data and an aching desire for an answer does not ensure that a reasonable answer can be extracted from a given body of data.” John Tukey
Florian Naudet@floriannaudet.bsky.social · 2mo agoSuper happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
Very happy to see Florian et al. tackle that smug term "real world evidence", which always sounded me like "University? I earned my degree at the school of hard knocks, mate"
Florian Naudet@floriannaudet.bsky.social · 2mo agoSuper happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
🔥 Kudos to our Irset / Université de Rennes postdoctoral researcher @fionar.bsky.social (UK) for being awarded, ex aequo with Farida Boubé Dobi, Ph.D. (Niger), the France Alumni Prize 2026 for Young Scientific Talent by Minister Delegate Éléonore Caroit yesterday at the Quai d’Orsay.
“Simply doing the best we can using routinely collected data is not good enough. No evidence for a research question may be preferable to evidence from a low quality routinely collected data study” doi.org/10.1136/bmj-...
doi.org
Florian Naudet@floriannaudet.bsky.social · 2mo agoSuper happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
"Real world" evidence is uncritically used to replace evidence from RCTs with inconvenient results. Experienced this in guideline panels. This paper seems to be a benchmark article to be used in such situations. Caveats with "real world", sorry, "routinely collected data" are explained in depth 👏👏👏
Florian Naudet@floriannaudet.bsky.social · 2mo agoSuper happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
Real world data is used as a term to make it sound like one of the strengths of the study design. It has no. meaningful definition and is used dishonestly to hide the weaknesses. Referees and journals should demand that the term be removed and the actual strengths and weaknesses are described.
Florian Naudet@floriannaudet.bsky.social · 2mo agoParticularly pleased to see two points that I strongly advocated for included in the paper: 1/ Using the term "routinely collected data" rather than "real-world evidence"...
Hallelujah - my personal take on "real world evidence/data" (as I see it used) is that it is a euphemism for data missing not at random
Florian Naudet@floriannaudet.bsky.social · 2mo agoParticularly pleased to see two points that I strongly advocated for included in the paper: 1/ Using the term "routinely collected data" rather than "real-world evidence"...
Very much appreciating the explicit mentions (and importance) of following the FAIR principles, transparency, and *code sharing* in this paper...
Florian Naudet@floriannaudet.bsky.social · 2mo agoSuper happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
Indeed! Randomization + routinely collected data go back to Richard Peto's call for 'large and simple trials' that inspired the hugely succesfull RECOVERY trial in COVID-19. Nicely summarized important points.
Super happy to have contributed to this super important and timely paper, "Using Routinely Collected Data for Research Purposes: Challenges and Mitigation Strategies", led by @sabinehoffmann11.bsky.social and just published in @bmj.com... www.bmj.com/content/393/...
bmj.com
